All News
HLA-B27 Testing in Practice
A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined.
Read Article
A Review of Intracranial GCA
A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.
Predictors and Outcomes in Systemic Sclerosis
EurekAlert!
The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.
Read Article
EULAR 2025 – Day 2 Report
Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.
Read Article
Aortic aneurysms w/ GCA. TriNetX study of 7,294 Bx-proven GCA vs 265,948 controls w/ tension HA. GCA had signif higher 5-yr risk of aortic aneurysms (3.59%; aHR 1.98), including thoracic thoracoabdominal & abdominal. Carotid A stenosis also incr in GCA (aHR 1.59) https://t.co/15fwlHa0FG
Dr. John Cush RheumNow ( View Tweet)
Several studies have shown predictive value to monocyte counts in RA responses. UK study of 246 #RA pts showed pretreatment absolute monocyte count [ORadj 9.56; 1.61-59.86, p = 0.01) predicted bDMARD nonresponse @ 6 mos. Replicates other reports! https://t.co/GqGj8R0wq1 https://t.co/HJ7wFBoxGE
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 Abstr#OP0265 Do we have convenient biomarkers to help predict new ANA+ referral who would progress to #SLE #Sjogren at 12 mths? Proteomics analysis identified IFN and B-cell markers. Validation is needed and to incorporate clinical items into prognostic model @RheumNow https://t.co/TWClLTKQ0b
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#POS0318 Single timepoint assessment may not show true picture of #SLE control. Data from BILAG-BR registry using machine learning showed 6 trajectories with clinical meaning:
-Nonresponse with high activity: dsDNA-ve & RNP+
-Response-flare: active MSK @RheumNow https://t.co/VrI8e4ONtM
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA?
🔹️245 pts
🔹️CRP recorded for past 5y
🔹️sustained high CRP in 40%
🔹️associated with ⬆️ cardiovascular risk factors, ⬇️endothelial function & subclin atheroslerosis
POS0714
#EULAR2025
@RheumNow https://t.co/jAlj3sr95H
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Despite the evolution of anti-synthetase antibodies, there’s a clear need for better ways to define the disease.
Enter the ACR/EULAR CLASS initiative - classification criteria for anti-synthetase syndrome
⬇️ see the next tweet
#EULAR2025 @RheumNow https://t.co/Z3rPOt1vlx
Links:
David Liew drdavidliew ( View Tweet)
1st #recommendations for
#Hemochromatosis #arthropathy
#psuedogout
#CPPD
#calcium #pyrophosphate #arthritis
#EULAR2025 #Recommenadations II
@RheumNow @eular_org https://t.co/AnE4T2wYoa
Janet Pope Janetbirdope ( View Tweet)
Procalcitonin can be used in the monitoring of infection, but is also high in Stills disease. 89 AOSD pts showed pts w high PCT had more pleuritis, MAS,^LFTs, & correlated w/ Dz activity, CRP, LDH, hi ferritin & normalized w bDMARD Rx. #EULAR2025 abstr #POS1118 https://t.co/NpRA9optd3
Dr. John Cush RheumNow ( View Tweet)
KORAIL cohort: new RA-ILD progression model (inc. DLCO, ILD pattern/extent, anti-CCP, ± KL-6) stratified risk with high sensitivity & specificity. Adding KL-6 boosted AUC to 0.75.
A step toward personalised care in RA-ILD.
@RheumNow #EULAR2025 #OP0328 https://t.co/AHqNFw40gk
Mrinalini Dey DrMiniDey ( View Tweet)
Prediction of PsA in PSO pts: does it work?
First predictive model using mainly clinical data and labs extracted from primary care
Performs well in the cohort it was trained w/ but not in validation cohort.
Often an issue with prediction models!
Needs more granularity than https://t.co/5cVgqfd4fX
Aurelie Najm AurelieRheumo ( View Tweet)
🔍MRI lesions in early axSpA vs non axSpA with chronic back pain:
-Data from SPACE cohort
-n 318 (214 axSpA vs 108 non-axSpA).
-Baseline imaging (CR and MRI) and at 2y f/u
-Minimal progression on CR in both early axSpA and non-axSpA CBP.
-On MRI, significant increase in the https://t.co/m5YOAiFUz1
Links:
Adela Castro AdelaCastro222 ( View Tweet)
In 1314 PsA patients, cumulative methotrexate dose was not associated with liver fibrosis (OR 0.99). Instead, higher BMI (OR 1.03) & diabetes (OR 5.03) were key drivers. MASLD, not MTX, may underlie fibrosis risk in PsA. APRI >0.7 used for fibrosis detection. Abstract#POS0111 https://t.co/zsX7NUOT9m
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Rheumatoid nodules are fascinating. If methotrexate nodulosis is a factor, why has their rate gone down when MTX use has gone up?
Environmental factors? Something else? It’s still a bit of a mystery - we still don’t know why
Christopher Edwards #EULAR2025 @RheumNow https://t.co/8LJYNRybve
Links:
David Liew drdavidliew ( View Tweet)
Acute Dactylitis in #Psoriatic_Arthritis
🔹️1216 patients Canada 🇨🇦
🔹️52% had at least one episode of acute dactylitis in a median 12 years
🔹️Positive association with HLA-B27 and HLA-B27/C02
🔹️No association with HLA-B51
#EULAR2025
@RheumNow
OP0180 by Kharouf et al. https://t.co/oNNMBcvVb4
Nelly ZIADE 🍀 Nellziade ( View Tweet)
KORAIL cohort
Prediction model for progression of RA-ILD at 3 years
A combination of classic clinical parameters incl DA , ILD pattern, ACPA KL-6 with AUC 0.75
HR=34 for progression in High risk group
Need validation in an external cohort
@RheumNow #EULAR2025 OP0329 https://t.co/LIvn1JCXPq
Aurelie Najm AurelieRheumo ( View Tweet)
LDCT to assess disease progression in early axSpA:
-Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+)
- LDCT at baseline and 2 years apart.
-Overall 22% pt with net disease progression.
-Spine progression most frequent on thoracic spine.
-Good reliability in assessing https://t.co/M2jkDusD41
Links:
Adela Castro AdelaCastro222 ( View Tweet)
